The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Tarek Mazzawi, Magdy El-Salhy, Gülen Arslan Lied, Trygve Hausken, Tarek Mazzawi, Magdy El-Salhy, Gülen Arslan Lied, Trygve Hausken

Abstract

Introduction: Interactions between the gut microbiota and enteroendocrine cells play important role in irritable bowel syndrome (IBS). Reduced stem cell densities and their differentiation into enteroendocrine cells may cause abnormal densities of the duodenal enteroendocrine cells in IBS patients.

Materials and methods: We aimed to investigate the effects of fecal microbiota transplantation (FMT) on stem cell differentiation into enteroendocrine cells as detected by neurogenin 3, stem cells as detected by Musashi 1, and the enteroendocrine cells in the duodenum of IBS patients. The study included 16 IBS patients according to Rome III criteria. Four patients were excluded. The remaining patients (n = 12, four females and eight males) were divided according to the cause of IBS into post-infectious (n = 6) and idiopathic (n = 6) IBS. They completed the following questionnaires before and 3 weeks after FMT: IBS-Symptom Severity Scoring system (IBS-SSS) and IBS-Symptom Questionnaire (IBS-SQ). Feces donated by healthy relatives of the patients were transplanted via gastroscope. Biopsies were taken from the descending part of the duodenum at baseline and 3 weeks after FMT. They were immunostained for neurogenin 3, Musashi 1, and all types of duodenal enteroendocrine cells and quantified by computerized image analysis. Microbiota analyses of feces collected just before and 3 weeks after FMT were performed using GA-map™ Dysbiosis test (Genetic Analysis AS, Oslo, Norway).

Results: The total scores for IBS-SSS and IBS-SQ were significantly improved 3 weeks after receiving FMT, P = 0.0009 and <0.0001, respectively. The stem cell densities of neurogenin 3 increased significantly following FMT (P = 0.0006) but not for Musashi 1 (P = 0.42). The cell densities of chromogranin A, cholecystokinin, gastric inhibitory peptide, serotonin, and somatostatin, but not for secretin, have significantly changed in both IBS groups after 3 weeks from receiving FMT.

Conclusion: More than two-thirds of IBS patients experienced improvement in their symptoms parallel to changes in the enteroendocrine cells densities 3 weeks after FMT. The changes in the enteroendocrine cell densities do not appear to be caused by changes in the stem cells or their early progenitors rather by changes in the differentiation progeny as detected by neurogenin 3. The study was retrospectively registered at ClinicalTrials.gov (ID: NCT03333291).

Clinical trial registration: ClinicalTrials.gov, identifier NCT03333291.

Keywords: cell densities; duodenum; fecal microbiota transplantation; gut hormones; irritable bowel syndrome; microbiota; neuroendocrine; stem cells.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Mazzawi, El-Salhy, Lied and Hausken.

Figures

Figure 1
Figure 1
Neurogenin 3 cell densities before and after fecal microbiota transplantation (FMT) in (A) total, (B) post-infectious and (C) idiopathic irritable bowel syndrome patients. The dotted line represents the mean cell densities for the healthy control group. *** indicates P < 0.001.
Figure 2
Figure 2
Neurogenin 3 immunoreactive cells in patients with irritable bowel syndrome (A) before and (B) after fecal microbiota transplantation.
Figure 3
Figure 3
Musashi 1 cell densities before and after fecal microbiota transplantation (FMT) in (A) total, (B) post-infectious and (C) idiopathic irritable bowel syndrome patients. The dotted line represents the mean cell densities for the healthy control group.
Figure 4
Figure 4
Secretin immunoreactive cells in patients with irritable bowel syndrome (A) before and (B) after fecal microbiota transplantation.

References

    1. Aroniadis O. C., Brandt L. J. (2013). Fecal Microbiota Transplantation: Past, Present and Future. Curr. Opin. Gastroenterol. 29 (1), 79–84. 10.1097/MOG.0b013e32835a4b3e
    1. Beucher A., Gjernes E., Collin C., Courtney M., Meunier A., Collombat P., et al. . (2012). The Homeodomain-Containing Transcription Factors Arx and Pax4 Control Enteroendocrine Subtype Specification in Mice. PloS One 7 (5), e36449. 10.1371/journal.pone.0036449
    1. Bixquert Jimenez M. (2009). Treatment of Irritable Bowel Syndrome With Probiotics. An Etiopathogenic Approach At Last? Rev. Esp. Enferm. Dig. 101 (8), 553–564. 10.4321/S1130-01082009000800006
    1. Bjerknes M., Cheng H. (2006). Neurogenin 3 and the Enteroendocrine Cell Lineage in the Adult Mouse Small Intestinal Epithelium. Dev. Biol. 300 (2), 722–735. 10.1016/j.ydbio.2006.07.040
    1. Cammarota G., Ianiro G., Gasbarrini A. (2014). Fecal Microbiota Transplantation for the Treatment of Clostridium Difficile Infection: A Systematic Review. J. Clin. Gastroenterol. 48 (8), 693–702. 10.1097/mcg.0000000000000046
    1. Cammarota G., Ianiro G., Tilg H., Rajilic-Stojanovic M., Kump P., Satokari R., et al. . (2017). European Consensus Conference on Faecal Microbiota Transplantation in Clinical Practice. Gut 66 (4), 569–580. 10.1136/gutjnl-2016-313017
    1. Cani P. D., Hoste S., Guiot Y., Delzenne N. M. (2007). Dietary non-Digestible Carbohydrates Promote L-cell Differentiation in the Proximal Colon of Rats. Br. J. Nutr. 98, 32–37. 10.1017/s0007114507691648
    1. Cani P. D., Knauf C. (2016). How Gut Microbes Talk to Organs: The Role of Endocrine and Nervous Routes. Mol. Metab. 5 (9), 743–752. 10.1016/j.molmet.2016.05.011
    1. Carroccio A., Brusca I., Mansueto P., Pirrone G., Barrale M., Di Prima L., et al. . (2010). A Cytologic Assay for Diagnosis of Food Hypersensitivity in Patients With Irritable Bowel Syndrome. Clin. Gastroenterol. Hepatol. 8, 254–260. 10.1016/j.cgh.2009.11.010
    1. Casen C., Vebo H. C., Sekelja M., Hegge F. T., Karlsson M. K., Ciemniejewska E., et al. . (2015). Deviations in Human Gut Microbiota: A Novel Diagnostic Test for Determining Dysbiosis in Patients With IBS or IBD. Aliment. Pharmacol. Ther. 42 (1), 71–83. 10.1111/apt.13236
    1. Chua A. S., Keeling P. W. (2006). Cholecystokinin Hyperresponsiveness in Functional Dyspepsia. World J. Gastroenterol. 12 (17), 2688–2693. 10.3748/wjg.v12.i17.2688
    1. Deftos L. J. (1991). Chromogranin A: its Role in Endocrine Function and as an Endocrine and Neuroendocrine Tumor Marker. Endocr. Rev. 12, 181–187. 10.1210/edrv-12-2-181
    1. Dizdar V., Spiller R., Singh G., Hanevik K., Gilja O. H., El-Salhy M., et al. . (2010). Relative Importance of Abnormalities of CCK and 5-HT (Serotonin) in Giardia-induced Post-Infectious Irritable Bowel Syndrome and Functional Dyspepsia. Aliment. Pharmacol. Ther. 31 (8), 883–891. 10.1111/j.1365-2036.2010.04251.x
    1. Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P. (2008). A Double Blind Randomized Controlled Trial of a Probiotic Combination in 100 Patients With Irritable Bowel Syndrome. Gastroenterol. Clin. Biol. 32 (2), 147–152. 10.1016/j.gcb.2007.06.001
    1. El-Salhy M. (2015). Recent Developments in the Pathophysiology of Irritable Bowel Syndrome. World J. Gastroenterol. 21 (25), 7621–7636. 10.3748/wjg.v21.i25.7621
    1. El-Salhy M., Gilja O. H. (2017). Abnormal Ileal Stem-, Neurogenin3- and Enteroendocrine Cells in Patients With Irritable Bowel Syndrome. Gastroenterology 152(5 (5 (1), 725–726. 10.1016/S0016-5085(17)32522-2
    1. El-Salhy M., Gilja O. H., Gundersen D., Hatlebakk J. G., Hausken T. (2014). Endocrine Cells in the Ileum of Patients With Irritable Bowel Syndrome. World J. Gastroenterol. 20 (9), 2383–2391. 10.3748/wjg.v20.i9.2383
    1. El-Salhy M., Gilja O. H., Gundersen D., Hatlebakk J. G., Hausken T. (2014). Interaction Between Ingested Nutrients and Gut Endocrine Cells in Patients With Irritable Bowel Syndrome (Review). Int. J. Mol. Med. 34 (2), 363–371. 10.3892/ijmm.2014.1811
    1. El-Salhy M., Gilja O. H., Gundersen D., Hatlebakk J. G., Hausken T. (2014). Duodenal Chromogranin a Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome. Gastroenterol. Res. Pract. 2014, 462856. 10.1155/2014/462856
    1. El-Salhy M., Gundersen D., Gilja O. H., Hatlebakk J. G., Hausken T. (2014). Is Irritable Bowel Syndrome an Organic Disorder? World J. Gastroenterol. 20 (2), 384–400. 10.3748/wjg.v20.i2.384
    1. El-Salhy M., Hatlebakk J. G., Gilja O. H., Brathen Kristoffersen A., Hausken T. (2019). Efficacy of Faecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome in a Randomised, Double-Blind, Placebo-Controlled Study. Gut (2020) 69 (5), 859–867. 10.1136/gutjnl-2019-319630
    1. El-Salhy M., Hatlebakk J. G., Hausken T. (2015). Reduction in Duodenal Endocrine Cells in Irritable Bowel Syndrome is Associated With Stem Cell Abnormalities. World J. Gastroenterol. 21 (32), 9577–9587. 10.3748/wjg.v21.i32.9577
    1. El-Salhy M., Hausken T., Gilja O. H., Hatlebakk J. G. (2017). The Possible Role of Gastrointestinal Endocrine Cells in the Pathophysiology of Irritable Bowel Syndrome. Expert Rev. Gastroenterol. Hepatol. 11, 139–148. 10.1080/17474124.2017.1269601
    1. El-Salhy M., Mazzawi T. (2018). Fecal Microbiota Transplantation for Managing Irritable Bowel Syndrome. Expert Rev. Gastroenterol. Hepatol. (2018) 12 (5), 439–445. 10.1080/17474124.2018.1447380
    1. El-Salhy M., Mazzawi T., Hausken T., Hatlebakk J. G. (2016). Interaction Between Diet and Gastrointestinal Endocrine Cells. BioMed. Rep. 4, 651–656. 10.3892/br.2016.649
    1. El-Salhy M., Vaali K., Dizdar V., Hausken T. (2010). Abnormal Small-Intestinal Endocrine Cells in Patients With Irritable Bowel Syndrome. Dig. Dis. Sci. 55 (12), 3508–3513. 10.1007/s10620-010-1169-6
    1. Everard A., Lazarevic V., Derrien M., Girard M., Muccioli G. G., Neyrinck A. M., et al. . (2011). Responses of Gut Microbiota and Glucose and Lipid Metabolism to Prebiotics in Genetic Obese and Diet-Induced Leptin-Resistant Mice. Diabetes 60 (11), 2775–2786. 10.2337/db11-0227
    1. Francis C. Y., Morris J., Whorwell P. J. (1997). The Irritable Bowel Severity Scoring System: A Simple Method of Monitoring Irritable Bowel Syndrome and its Progress. Aliment. Pharmacol. Ther. 11 (2), 395–402. 10.1046/j.1365-2036.1997.142318000.x
    1. Greiner T. U., Backhed F. (2016). Microbial Regulation of GLP-1 and L-cell Biology. Mol. Metab. 5 (9), 753–758. 10.1016/j.molmet.2016.05.012
    1. Halkjaer S. I., Christensen A. H., Lo B. Z. S., Browne P. D., Gunther S., Hansen L. H., et al. . (2018). Faecal Microbiota Transplantation Alters Gut Microbiota in Patients With Irritable Bowel Syndrome: Results From a Randomised, Double-Blind Placebo-Controlled Study. Gut 67 (12), 2107–2115. 10.1136/gutjnl-2018-316434
    1. Hong S. N., Rhee P. L. (2014). Unraveling the Ties Between Irritable Bowel Syndrome and Intestinal Microbiota. World J. Gastroenterol. 20, 2470–2481. 10.3748/wjg.v20.i10.2470
    1. Ianiro G., Eusebi L. H., Black C. J., Gasbarrini A., Cammarota G., Ford A. C. (2019). Systematic Review With Meta-Analysis: Efficacy of Faecal Microbiota Transplantation for the Treatment of Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 50 (3), 240–248. 10.1111/apt.15330
    1. Johnsen P. H., Hilpusch F., Cavanagh J. P., Leikanger I. S., Kolstad C., Valle P. C., et al. . (2018). Faecal Microbiota Transplantation Versus Placebo for Moderate-to-Severe Irritable Bowel Syndrome: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Single-Centre Trial. Lancet Gastroenterol. Hepatol. 3 (1), 17–24. 10.1016/S2468-1253(17)30338-2
    1. Kane S. V., Sandborn W. J., Rufo P. A., Zholudev A., Boone J., Lyerly D., et al. . (2003). Fecal Lactoferrin is a Sensitive and Specific Marker in Identifying Intestinal Inflammation. Am. J. Gastroenterol. 98 (6), 1309–1314. 10.1111/j.1572-0241.2003.07458.x
    1. Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., et al. . (2007). The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects. Gastroenterology 133 (1), 24–33. 10.1053/j.gastro.2007.04.005
    1. Malikowski T., Khanna S., Pardi D. S. (2017). Fecal Microbiota Transplantation for Gastrointestinal Disorders. Curr. Opin. Gastroenterol. 33, 8–13. 10.1097/mog.0000000000000326
    1. Mathias J. R., Clench M. H., Reeves-Darby V. G., Fox L. M., Hsu P. H., Roberts P. H., et al. . (1994). Effect of Leuprolide Acetate in Patients With Moderate to Severe Functional Bowel Disease. Double-blind, Placebo-Controlled Study. Dig. Dis. Sci. 39 (6), 1155–1162. 10.1007/BF02093778
    1. Mazzawi T., El-Salhy M. (2017). Changes in Duodenal Enteroendocrine Cells in Patients With Irritable Bowel Syndrome Following Dietary Guidance. Exp. Biol. Med. 10.1177/1535370217699537
    1. Mazzawi T., El-Salhy M. (2017). Effect of Diet and Individual Dietary Guidance on Gastrointestinal Endocrine Cells in Patients With Irritable Bowel Syndrome (Review). Int. J. Mol. Med. 40 (4), 943–952. 10.3892/ijmm.2017.3096
    1. Mazzawi T., Hausken T., Hov J. R., Valeur J., Sangnes D. A., El-Salhy M., et al. . (2019). Clinical Response to Fecal Microbiota Transplantation in Patients With Diarrhea-Predominant Irritable Bowel Syndrome is Associated With Normalization of Fecal Microbiota Composition and Short-Chain Fatty Acid Levels. Scand. J. Gastroenterol. 54 (6), 690–699. 10.1080/00365521.2019.1624815
    1. Mazzawi T., Lied G. A., Sangnes D. A., El-Salhy M., Hov J. E. R., Gilja O. H., et al. . (2018). The Kinetics of Gut Microbial Community Composition in Patients With Irritable Bowel Syndrome Following Fecal Microbiota Transplantation. PloS One 13 (11), e0194904. 10.1371/journal.pone.0194904
    1. Mentis N., Vardarli I., Kothe L. D., Holst J. J., Deacon C. F., Theodorakis M., et al. . (2011). GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes. Diabetes 60 (4), 1270–1276. 10.2337/db10-1332
    1. Montgomery R. K., Breault D. T. (2008). Small Intestinal Stem Cell Markers. J. Anat. 213, 52–58. 10.1111/j.1469-7580.2008.00925.x
    1. Nohr M. K., Pedersen M. H., Gille A., Egerod K. L., Engelstoft M. S., Husted A. S., et al. . (2013). GPR41/FFAR3 and GPR43/FFAR2 as Cosensors for Short-Chain Fatty Acids in Enteroendocrine Cells vs FFAR3 in Enteric Neurons and FFAR2 in Enteric Leukocytes. Endocrinology 154 (10), 3552–3564. 10.1210/en.2013-1142
    1. Ohman L., Simren M. (2013). Intestinal Microbiota and its Role in Irritable Bowel Syndrome (IBS). Curr. Gastroenterol. Rep. 15 (5):323. 10.1007/s11894-013-0323-7
    1. Pinn D. M., Aroniadis O. C., Brandt L. J. (2014). Is Fecal Microbiota Transplantation the Answer for Irritable Bowel Syndrome? A Single-Center Experience. Am. J. Gastroenterol. 109 (11), 1831–1832. 10.1038/ajg.2014.295
    1. Reigstad C. S., Salmonson C. E., Rainey J. F., 3rd3rd, Szurszewski J. H., Linden D. R., Sonnenburg J. L., et al. . (2015). Gut Microbes Promote Colonic Serotonin Production Through an Effect of Short-Chain Fatty Acids on Enterochromaffin Cells. FASEB J. 29 (4), 1395–1403. 10.1096/fj.14-259598
    1. Salet G. A., Samsom M., Roelofs J. M., van Berge Henegouwen G. P., Smout A. J., Akkermans L. M. (1998). Responses to Gastric Distension in Functional Dyspepsia. Gut 42 (6), 823–829. 10.1136/gut.42.6.823
    1. Sisson G., Ayis S., Sherwood R. A., Bjarnason I. (2014). Randomised Clinical Trial: A Liquid Multi-Strain Probiotic vs. Placebo in the Irritable Bowel Syndrome–a 12 Week Double-Blind Study. Aliment. Pharmacol. Ther. 40 (1), 51–62. 10.1111/apt.12787
    1. Si J. M., Yu Y. C., Fan Y. J., Chen S. J. (2004). Intestinal Microecology and Quality of Life in Irritable Bowel Syndrome Patients. World J. Gastroenterol. 10 (12), 1802–1805. 10.3748/wjg.v10.i12.1802
    1. Sternini C., Anselmi L., Rozengurt E. (2008). Enteroendocrine Cells: A Site of ‘Taste’ in Gastrointestinal Chemosensing. Curr. Opin. Endocrinol. Diabetes Obes. 15, 73–78. 10.1097/MED.0b013e3282f43a73
    1. Stock S., Leichner P., Wong A. C., Ghatei M. A., Kieffer T. J., Bloom S. R., et al. . (2005). Ghrelin, Peptide YY, Glucose-Dependent Insulinotropic Polypeptide, and Hunger Responses to a Mixed Meal in Anorexic, Obese, and Control Female Adolescents. J. Clin. Endocrinol. Metab. 90 (4), 2161–2168. 10.1210/jc.2004-1251
    1. Taupenot L., Harper K. L., O’Connor D. T. (2003). The Chromogranin-Secretogranin Family. N. Engl. J. Med. 348, 1134–1149. 10.1056/NEJMra021405
    1. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E. G., de Vos W. M., et al. . (2013). Duodenal Infusion of Donor Feces for Recurrent Clostridium Difficile. N. Engl. J. Med. 368 (5), 407–415. 10.1056/NEJMoa1205037
    1. Varga G., Balint A., Burghardt B., D’Amato M. (2004). Involvement of Endogenous CCK and CCK1 Receptors in Colonic Motor Function. Br. J. Pharmacol. 141 (8), 1275–1284. 10.1038/sj.bjp.0705769
    1. Wendelbo I., Mazzawi T., El-Salhy M. (2014). Increased Serotonin Transporter Immunoreactivity Intensity in the Ileum of Patients With Irritable Bowel Disease. Mol. Med. Rep. 9 (1), 180–184. 10.3892/mmr.2013.1784
    1. Whorwell P. J., Altringer L., Morel J., Bond Y., Charbonneau D., O’Mahony L., et al. . (2006). Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women With Irritable Bowel Syndrome. Am. J. Gastroenterol. 101 (7), 1581–1590. 10.1111/j.1572-0241.2006.00734.x
    1. Wichmann A., Allahyar A., Greiner T. U., Plovier H., Lunden G. O., Larsson T., et al. . (2013). Microbial Modulation of Energy Availability in the Colon Regulates Intestinal Transit. Cell Host Microbe 14 (5), 582–590. 10.1016/j.chom.2013.09.012
    1. World Medical Association Declaration of Helsinki (2013). Ethical Principles for Medical Research Involving Human Subjects. Jama 310 (20), 2191–2194. 10.1001/jama.2013.281053
    1. Xu D., Chen V. L., Steiner C. A., Berinstein J. A., Eswaran S., Waljee A. K., et al. . (2019). Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am. J. Gastroenterol. 114 (7), 1043–1050. 10.14309/ajg.0000000000000198

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner